meta
|
Preg
- medecines during pregnancy KB
Search
Naratriptan
Overall results
Study description
Excluded studies
Table
Graphic
auto
during pregnancy (anytime or not specified)
1st trimester
2nd trimester
3rd trimester
2nd and/or 3rd trimester
throughout pregnancy
early pregnancy
days before delivery
late pregnancy
preconception-only
periconceptional
preconceptional for kinetic reason
at least 1st trimester
3 months (or more) before pregnancy or during pregnancy
1st and 2nd trimester
3 months or more before pregnancy or1st trimester
Whatever the period exposition
individual studies
Outcome
TE
95% CI
n cases
n exposed
k
Pub. bias
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)
Källén (control unexposed, disease free), 2011 Ephross (Naratriptan versus Sumatriptan), 2014 Yusuf (Control exposed to Sumatriptan), 2018
3
0.50
[
0.14
; 1.77]
56,846
161
not evaluable
Major congenital malformations
Ephross (Naratriptan versus Sumatriptan), 2014 Yusuf (Control exposed to Sumatriptan), 2018
2
0.31
[
0.06
; 1.63]
86
139
not evaluable
Intrauterine deaths
Early intrauterine death (< 22 weeks)
Ephross (Naratriptan versus Sumatriptan), 2014 Yusuf (Control exposed to Sumatriptan), 2018
2
1.02
[
0.71
; 1.46]
701
242
not evaluable
Elective/induced termination of pregnancy
Ephross (Naratriptan versus Sumatriptan), 2014 Yusuf (Control exposed to Sumatriptan), 2018
2
0.91
[
0.44
; 1.87]
160
247
not evaluable
Late intrauterine deaths (> 22 weeks)
Ephross (Naratriptan versus Sumatriptan), 2014 Yusuf (Control exposed to Sumatriptan), 2018
2
0.79
[
0.10
; 5.99]
19
247
not evaluable
0.0
10.0
1.0
